November 13, 2017

INTERVIEW: SatoshiPay dump Bitcoin in favour of Stellar Development Foundation

Blue Star Capital plc (LON:BLU) CEO Tony Fabrizi & SatoshiPay founder Meinhard Benn talk to DirectorsTalk about dropping Bitcoin (CURRENCY:BTC) as the underlying cryptocurrency ledger in favour of Stellar Development..

Anglo Pacific Group plc Q&A with CEO Julian Treger (LON:APF)

Anglo Pacific Group plc (LON:APF) Chief Executive Officer Julian Treger caught up with DirectorsTalk for an exclusive interview to discuss their recent trading update   Q1: We note a trading..

Warpaint London PLC Acquisition of Retra Holdings Limited

Warpaint London PLC (LON:W7L), the specialist supplier of colour cosmetics and owner of the W7 brand, has today announced the proposed acquisition of Retra Holdings Limited (“Retra”) and a placing..

Blue Star Capital Update on SatoshiPay

Blue Star Capital plc (LON:BLU), the investing company with a focus on technology and its applications within media and gaming, has today announced that its investee company, SatoshiPay Ltd (“SatoshiPay”),..

Nektan PLC Partners with Videoslots.com

Nektan plc (LON:NKTN), a leading international B2B gaming solutions and services provider, has integrated its wide range of content with Videoslots.com (“Videoslots”), the online casino. As part of the agreement,..

Glencore completes acquisition of Volcan shares

Glencore Plc (LON:GLEN) refers to its announcement of 3 October 2017, in which it announced that it intended to make an offer to all of Volcan’s shareholders via a public..

Rio Tinto Plc successfully completes A$750 million off-market buy-back

Rio Tinto plc (LON:RIO) has successfully completed its off-market buy-back of Rio Tinto Limited shares, which was increased to A$750 million from the indicative A$700 million announced due to strong..

Allergy Therapeutics Plc to Present at Jefferies 2017 London Healthcare Conference

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced today that Manuel Llobet, Chief Executive Officer, will be presenting at the Jefferies 2017 Healthcare..

C4X Discovery Holdings plc Presents data on lead addiction programme: Orexin-1 antagonist

C4X Discovery Holdings plc (LON:C4XD), a pioneering drug discovery company, presented new pre-clinical data on its Orexin-1 antagonist programme at Neuroscience 2017 on 11th November 2017 in Washington, DC. C4XD’s..

Search

Funds

November 13, 2017

Search

Funds

November 13, 2017

FTSE 100

Funds